In the treatment of hypertension in patients with metabolic syndrome and/or diabetes mellitus, ACE inhibitors (or sartans) and calcium channel blockers are preferred for well-known nephroprotective, angioprotective, and metabolic effects. This evidence concerns the gene ACE and diabetes mellitus.